Closed-loop insulin pump preventing nocturnal hypoglycemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for preventing nocturnal hypoglycemia in diabetes patients are inaccurate and rely on patient intuition, leading to potential severe episodes and long-term morbidity due to asymptomatic hypoglycemia and defective glucose counterregulation.
Innovation Solution
A device and method that continuously monitor glucose levels and deliver insulin bolus doses, using parameters like insulin sensitivity, carbohydrate-to-insulin ratio, and residual insulin to advise patients on carbohydrate consumption and insulin adjustments to prevent hypoglycemia, with options for automatic or user-confirmed modifications to basal insulin rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If continuous subcutaneous insulin injection (CSII) with insulin pumps is used to deliver insulin at a continuous basal rate, then flexibility in dose administration and liberation from repeated injections is improved, but the risk of nocturnal hypoglycemia increases due to nocturnal hyperinsulinemia
Solution Approach 1:
The device incorporates a glucose sensor that continuously monitors blood glucose levels and feeds this information back to the control unit. The control unit automatically adjusts the basal insulin rate based on real-time glucose readings, preventing both hypoglycemia and hyperglycemia. This closed-loop feedback system resolves the contradiction by maintaining the flexibility of continuous insulin delivery while preventing the harmful effect of nocturnal hypoglycemia.
Solution Approach 2:
The system dynamically adjusts the basal insulin rate throughout the day and night based on glucose levels, activity, and insulin sensitivity changes. The pump can modify delivery rates in real-time rather than using fixed predetermined rates, allowing optimization of insulin delivery to prevent nocturnal hypoglycemia while maintaining operational flexibility.
2Reliability
If frequent glucose measurements and adjustment of insulin delivery are implemented to maintain normoglycemia, then glycemic control is improved, but device complexity and monitoring requirements increase
Solution Approach 1:
The system combines the glucose sensor, control unit, and insulin pump into a single integrated device. The sensor continuously monitors glucose levels, the control unit processes this data along with user input parameters (insulin sensitivity, carbohydrate-to-insulin ratio, residual insulin), and automatically adjusts insulin delivery through the pump. This integration simplifies the overall system while maintaining reliable glycemic control.
Solution Approach 2:
The device performs automatic insulin dose adjustments based on glucose sensor readings and pre-programmed parameters. The system self-regulates insulin delivery without requiring manual calculation or intervention for each dose adjustment, reducing the complexity of user interaction while maintaining reliable glycemic control.
3Loss of time
If asymptomatic nocturnal hypoglycemia is left undetected, then monitoring burden is reduced, but the Somogyi phenomenon occurs causing hyperglycemia and clinically important deterioration in glycemic control
Solution Approach 1:
The glucose sensor operates continuously throughout the day and night, providing uninterrupted glucose level monitoring. This continuous monitoring detects asymptomatic nocturnal hypoglycemia immediately when it occurs, preventing the Somogyi phenomenon and maintaining stable glycemic control without imposing additional monitoring burden on the user.
Data Source
Figure 1~2a
Figure 2b~3
Figure 4a~4b
AI summary
A device and a method are provided that can be used for prevention of hypoglycemia. The device for prevention of hypoglycemia comprises a module adapted for receiving a target blood glucose (TBG) level corresponding to a desired level of glucose in a patient's body during a fasting time period; a module adapted for receiving a fasting time blood glucose (BBG) level corresponding to the level of glucose in the patient's body substantially at the beginning of the fasting time period; a module adapted for receiving a first set of parameters corresponding to a medical state of the patient; a module adapted for determining a therapeutic course of action based on the levels of the TBG, BBG and the medical state of the patent; and, a module adapted for administering the therapeutic course of action to the patient.